Wave Life Sciences Ltd (WVE)
Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on RNA medicines. Its PRISM platform combines multiple therapeutic modalities, chemistry capabilities, and human genetics insights to support the discovery and development of treatments for both rare and common diseases. The company is advancing several product candidates, including WVE-006 for alpha-1 antitrypsin deficiency, WVE-007 for obesity, WVE-008 for liver disease, WVE-N531 for Duchenne muscular dystrophy, and WVE-003 for Huntington’s disease. Wave also has collaboration agreements with GlaxoSmithKline, Takeda Pharmaceutical Company Limited, and Asuragen, Inc. covering research, development, commercialization, and companion diagnostics activities tied to selected oligonucleotide programs. Founded in 2012, the company is based in Singapore.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-WVE
|
$5.75
|
32.2% Upside
|
Undervalued
|
$18.53
|
326.0% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
1.9x
|
13.1x
|
857.2 M
|
410.1 M
|
4.9%
|
48.0%
|
1.0
|
95.4%
|
